#9
06/10/02

A116 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner	:	Not Yet Assigned
Group	:	1645
Applicant	:	Stephen M. Strittmatter, et al.
Application No.	:	09/972,546
Confirmation No.	:	4440
Filed	:	October 6, 2001
For	:	NOGO RECEPTOR HOMOLOGS

New York, New York
February 22, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §§ 1.97 AND 1.56

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant makes of record the following documents, copies of which are submitted herewith:*

UNITED STATES PATENTS

5,250,414, Schwab et al., issued October 5, 1993
5,684,133, Schwab et al., issued November 4, 1997
5,858,708, Bandman et al, issued January 12, 1999
6,025,333, Schwab et al., issued February 15, 2000

---

* A completed Form PTO-1449 listing these documents is attached hereto.

FOREIGN PATENT APPLICATIONS

WO 98/06841, published February 19, 1998
WO 99/46281, published September 16, 1999
WO 99/66041, published December 23, 1999
WO 00/05364, published February 3, 2000
WO 00/31235, published June 2, 2000
WO 00/32221, published June 8, 2000
WO 00/37638, published June 29, 2000
WO 00/53756, published September 14, 2000
WO 00/53758, published September 14, 2000
WO 00/58473, published October 5, 2000
WO 00/70050, published November 23, 2000
WO 00/73452, published December 7, 2000
WO 01/09162, published February 8, 2001
WO 01/51520, published July 19, 2001

REFERENCES

C.E. Bandtlow, et al., "NI-35/250/Nogo-A: A Neurite Growth Inhibitor Restricting Structural Plasticity and Regeneration of Nerve Fibers in the Adult Vertebrate CNS," Glia, 29(2), pp. 175-181 (2000).

M.S. Chen, et al., "Nogo-A is a Myelin-Associated Neurite Outgrowth Inhibitor and an Antigen for Monoclonal Antibody IN-1," Nature, 403(6768), pp. 434-439 (2000).

A.E. Fournier, et al., "Identification of a Receptor Mediating Nogo-66 Inhibition of Axonal Regeneration," Nature, 409(6818), pp. 341-346 (2001).

T. GrandPre, et al., "Identification of the Nogo Inhibitor of Axon Regeneration as a Reticulon Protein," Nature, 403(6768), pp. 439-444 (2000).

P. Hu, et al., "Homo Sapiens Chromosome 22q11 PAC Clone p215k21 Distal to DGCR Region," EMBL Database Entry AC006549, Accession No. AC006549 (1999).

A.B. Huber, et al., "Nogo-A, a Potent Inhibitor of Neurite Outgrowth and Regeneration," Biol. Chem., 381(5-6), pp. 407-419 (2000).

D. Merkler, et al., "Locomotor Recovery in Spinal Cord-Injured Rats Treated with an Antibody Neutralizing the Myelin-Associated Neurite Growth Inhibitor Nogo-A," J. Neurosci., 21(10), pp. 3665-3673 (2001).

M. Oudega, et al., "Neutralizing Antibodies Against Neurite Growth Inhibitor NI-35/250 Do Not Promote Regeneration of Sensory Axons in the Adult Rat Spinal Cord," Neuroscience, 100(4), pp. 873-883 (2000).

R. Prinjha, et al., "Inhibitor of Neurite Outgrowth in Humans," Nature, 403(6768), pp. 383-384 (2000).

O. Raineteau, et al., "Sprouting and Regeneration After Pyramidotomy and Blockade of the Myelin-Associated Neurite Growth Inhibitors N1 35/250 in Adult Rats," Eur. J. Neurosci., 11(4), pp. 1486-1490 (1999).

O. Raineteau, et al., "Functional Switch Between Motor Tracts in the Presence of the mAB IN-1 in the Adult Rat," Proc. Natl. Acad. Sci. U.S.A., 98(12), pp. 6929-6934 (2001).

A.A. Spillmann, et al., "Identification and Characterization of a Bovine Neurite Growth Inhibitor (bNI-22)," J. Biol. Chem., 273(30), pp. 19283-19293 (1998).

M. Tatagiba, et al., "Regeneration of Injured Axons in the Adult Mammalian Central Nervous System," Neurosurgery, 40(3), pp. 541-547 (1997).

M. Thallmair, et al., "Neurite Growth Inhibitors Restrict Plasticity and Functional Recovery Following Corticospinal Tract Lesions," Nat. Neurosci., 1(2), pp. 124-131 (1998).

W.J. Z'Graggen, et al., "Functional Recovery and Enhanced Corticofugal Plasticity After Unilateral Pyramidal Tract Lesion and Blockade of Myelin-Associated Neurite Growth Inhibitors in Adult Rats," J. Neurosci., 18(12), pp. 4744-4757 (1998).

Applicant requests that these documents be (1) fully considered by the Examiner during the examination of this application; and (2) printed on any patent that may issue from this pplication. Applicant also requests that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

This Statement is being filed more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this

Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this Statement is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Barbara A. Ruskin (Reg. No. 39,350)
Attorneys for Applicant
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000
Fax.: (212) 596-9090

I Hereby Certify that this Correspondence is being Deposited with the U.S. Postal Service as First Class Mail in an Envelope Addressed to:
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231 on

February 22, 2002
Lillian Garcia



Signature of Person Signing